STOCK TITAN

Cidara Therapeutics, Inc. - CDTX STOCK NEWS

Welcome to our dedicated page for Cidara Therapeutics news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Therapeutics stock.

Cidara Therapeutics, Inc. (CDTX), headquartered in San Diego, California, is a pioneering biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. The company's mission is to address diseases inadequately treated by current standard of care therapies. Utilizing its proprietary Cloudbreak® platform, Cidara develops drug-Fc conjugates (DFCs) aimed at saving lives and improving patient outcomes for serious diseases such as cancer, viral infections, and autoimmune diseases.

The company's core portfolio includes:

  • Rezafungin (REZZAYO™): An FDA and EC-approved treatment for invasive candidiasis, licensed to multiple partners for commercialization in the U.S. and internationally.
  • CD101 IV: A potential once-weekly intravenous therapy for systemic fungal infections.
  • CD101 Topical: The first topical application of the echinocandin class of anti-fungals for vulvovaginal candidiasis (VVC).
  • CD388: A long-acting antiviral investigational drug for the prevention of all strains of influenza A and B, currently in Phase 2b development.

Recent achievements include significant data presentations at prestigious conferences and strategic realignments to focus on the most promising components of their pipeline. Cidara’s financial stability is reinforced by a $240 million private placement led by RA Capital Management, with participation from top-tier investors like Bain Capital Life Sciences and Biotech Value Fund (BVF).

Noteworthy partnerships include collaborations with Johnson & Johnson for CD388 and Mundipharma for the divestiture of rezafungin, which has led to substantial cost savings and allows Cidara to focus on its Cloudbreak platform. The company is also preparing for a Phase 2b clinical trial of CD388, aiming to deliver universal, season-long protection against influenza.
For more information, visit www.cidara.com.

Rhea-AI Summary
Cidara Therapeutics will present highlights from its ongoing preclinical studies of CD421 and the development of its novel drug-Fc conjugates at the Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
-
Rhea-AI Summary
Cidara Therapeutics presents positive preclinical data on CD388, a drug-Fc conjugate candidate targeting influenza A and B, at the ISIRV conference. CD388 shows activity against seasonal and pandemic influenza strains, including neuraminidase-resistant strains. The company is advancing its Cloudbreak DFC program in a Phase 2a trial and is also developing an oncology DFC candidate, CD421.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) has announced the FDA approval of REZZAYO™ (rezafungin for injection), a novel once-weekly echinocandin for treating candidemia and invasive candidiasis. The company received a $20 million milestone payment from Melinta Therapeutics, which acquired U.S. commercialization rights for REZZAYO. This marks the first new echinocandin approved in over a decade, addressing urgent treatment needs. Cidara is also eligible for an additional $47 million in milestones from existing partnerships based on successful completion of planned activities. With a year-end cash balance of $32.7 million and additional funding, Cidara aims to extend its cash runway. The company continues advancing its drug-Fc conjugate programs in oncology and autoimmune indications, with positive data from a Phase 2a trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) announced that Jeffrey Stein, Ph.D., the President and CEO, will participate in two upcoming investor conferences. The first is the Cantor Fitzgerald Future of Oncology Virtual Symposium on April 3, 2023, at 11:00 am ET, where he will take part in a panel discussion. The second event is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 pm ET, featuring a presentation and one-on-one investor meetings. Cidara's presentation at the Needham Conference will be available on-demand, with a replay accessible for 90 days. The company focuses on long-acting therapeutics for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
-
Rhea-AI Summary

Cidara Therapeutics, Inc. (Nasdaq: CDTX) has announced significant developments in its financial results for the year ending December 31, 2022, and updated its product pipeline. The company achieved a revenue of $64.3 million, an increase from $49.6 million in 2021, aided by a $25.9 million milestone recognized in connection with Melinta Therapeutics. Cidara received FDA approval for rezafungin, marking the first new treatment for candidemia in over a decade, enabling a $20 million milestone payment. Additionally, Cidara raised $28.4 million through public offerings. The net loss narrowed to $29.8 million from $42.5 million in 2021, demonstrating improved financial health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
Rhea-AI Summary

REZZAYO, a novel echinocandin from Cidara Therapeutics, has received FDA approval for treating candidemia and invasive candidiasis in adults lacking alternative treatment options. This marks the first new echinocandin approval in over a decade. The approval is based on successful data from the ReSTORE Phase 3 trial, demonstrating non-inferiority to caspofungin. REZZAYO, administered once weekly, aims to simplify treatment for patients facing serious fungal infections. The drug is expected to be commercially available by summer 2023, with Melinta Therapeutics overseeing its launch in the U.S., leveraging their expertise in acute care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) recently presented preclinical data on its CD73-targeting drug-Fc conjugate, CBO-212, at the ESMO Targeted Anticancer Therapies Congress in Paris (March 6-8, 2023). This marks a significant advancement in their oncology efforts, showcasing the anti-tumor potential of CBO-212. The data highlighted its ability to inhibit both soluble and cell-anchored CD73, restore immune cell activation, and induce receptor internalization, leading to tumor reduction in mouse models. Cidara is also advancing a refined version, CD421, with lower immunogenic properties. The company is committed to developing long-acting therapeutics to enhance patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary

Cidara Therapeutics, Inc. (Nasdaq: CDTX) has successfully completed its separate underwritten public offerings, securing gross proceeds of approximately $19.5 million. This includes the sale of 11,086,000 shares of common stock and 286,000 shares of Series X Convertible Preferred Stock, with the underwriter fully exercising its option for an additional 1,446,000 shares. The offerings were executed under an effective shelf registration statement with the SEC. Funds raised are intended to advance Cidara's long-acting therapeutics portfolio, focused on improving care for serious diseases, including its lead antifungal candidate, rezafungin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced the pricing of two separate public offerings totaling approximately $17.5 million. The company plans to offer 9,640,000 shares of common stock and 286,000 shares of Series X Convertible Preferred Stock, convertible into 2,860,000 shares of common stock. The offerings are expected to close around March 7, 2023. An additional 1,446,000 shares may be purchased by the underwriter within 30 days. Cantor Fitzgerald & Co. serves as the sole book-running manager. The offerings aim to enhance Cidara's financial position to support its therapeutic developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.09%
Tags

FAQ

What is the current stock price of Cidara Therapeutics (CDTX)?

The current stock price of Cidara Therapeutics (CDTX) is $23.22 as of December 20, 2024.

What is the market cap of Cidara Therapeutics (CDTX)?

The market cap of Cidara Therapeutics (CDTX) is approximately 252.1M.

What is Cidara Therapeutics' primary focus?

Cidara Therapeutics focuses on discovering, developing, and commercializing novel anti-infectives and immunotherapies for diseases inadequately treated by current therapies.

What is the Cloudbreak® platform?

The Cloudbreak® platform is Cidara's proprietary technology used to develop drug-Fc conjugates (DFCs) that target serious diseases by combining small molecules and peptides with human antibody fragments.

What are some of Cidara's key products?

Key products include REZZAYO™ (rezafungin) for invasive candidiasis, CD101 IV for systemic fungal infections, CD101 Topical for vulvovaginal candidiasis, and CD388 for the prevention of influenza A and B.

Has Cidara received any approvals for its products?

Yes, Cidara has received FDA and EC approval for REZZAYO™ (rezafungin) for the treatment of invasive candidiasis.

What recent strategic decisions has Cidara made?

Cidara recently divested rezafungin to Mundipharma, resulting in significant cost savings, and reacquired the global rights to CD388 from Johnson & Johnson to focus on their Cloudbreak platform.

How is Cidara funded?

Cidara is funded through investments, including a $240 million private placement led by RA Capital Management, and milestone payments from collaborations with partners like Mundipharma and Johnson & Johnson.

What upcoming clinical trials does Cidara have?

Cidara is planning to initiate a Phase 2b clinical trial to evaluate the efficacy and safety of CD388 as a universal preventative for influenza.

Where is Cidara Therapeutics headquartered?

Cidara Therapeutics is headquartered in San Diego, California.

Who are Cidara's major partners?

Major partners include Johnson & Johnson for CD388 and Mundipharma for rezafungin.

How can I get more information about Cidara?

For more information, you can visit Cidara's official website at www.cidara.com.

Cidara Therapeutics, Inc.

Nasdaq:CDTX

CDTX Rankings

CDTX Stock Data

252.14M
10.85M
4.73%
51.86%
0.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO